Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: UNIPROT:P56851 (
epididymal
)
11,273
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
In this study, morphological examination and computer-assisted sperm analysis (CASA) of
epididymal
spermatozoa in non-treated Crj:CD(SD)
IGS
rats were performed, and the relationship between the data obtained and the retention of step 19 spermatids in Stage IX to XI seminiferous tubules was examined. Retention of step 19 spermatids in Stage IX to XI seminiferous tubules was observed in all 50 untreated males, and the incidence ranged from 3.3% to 100%. Eighteen animals showed a high incidence of retention (74.7 +/- 14.2%, HIR for short), and the others showed a low incidence (24.9 +/- 11.0%, LIR for short). Although the incidence of retention in Stage X and XI seminiferous tubules was very low in LIR males, it was high in HIR males (1.8 +/- 3.0% vs 58.6 +/- 23.2%). Morphological abnormalities of sperms in the caudal region of the epididymis, mainly amorphous head and no head, were more frequently observed in HIR males than in LIR males (36.2 +/- 28.5% vs 1.8 +/- 1.2%). Sperm analysis also revealed some differences between HIR and LIR males: sperm motility in HIR males was severely lower than that in LIR males, and sperm velocity, beat/cross frequency and amplitude of lateral head displacement in HIR males were lower than the corresponding values in LIR males. In summation, retention of step 19 spermatids frequently occurred in the non-treated Crj:CD(SD)
IGS
males, and a relationship between the retention of these spermatids and sperm abnormalities, such as morphologically abnormal sperms, low motility and other items revealed by sperm analysis (CASA), was suggested.
...
PMID:Sperm abnormalities and histopathological changes in the testes in Crj:CD(SD)IGS rats. 1007 38
In association with the international validation project to establish a test protocol for the 'Enhanced OECD Test Guideline 407', we performed a preliminary 28-day, repeated-dose toxicity study of flutamide, a non-steroidal androgen antagonist, and assessed the sensitivity of a list of parameters for detecting endocrine-related effects of endocrine-disrupting chemicals (EDCs). Seven-week-old CD(SD)
IGS
rats were divided into four groups, each consisting of 10 males and 10 females, and administered flutamide once daily by oral gavage at doses of 0 (control), 0.25, 1 and 4 mg/kg body weight/day. Male rats were killed 1 day after the 28th administration. Female rats were killed on the day they entered the diestrus stage in the estrous cycle following the last treatment. Male rats receiving flutamide at dose levels of 1 and 4 mg/kg showed lobular atrophy of the mammary gland and a decrease in
epididymal
weight. In addition, 4 mg/kg flutamide-treated males exhibited raised serum testosterone and estradiol levels and decreased weight of the accessory sex glands. In females, a slight prolongation of the estrous cycle was also observed in the 4 mg/kg flutamide-treated group. No dose-related changes could be detected by haematology, serum biochemistry and sperm analysis. Thus, among the parameters tested in the present experimental system, the weight of endocrine-linked organs and their histopathological assessment, serum hormone levels, and estrous cycle stage allowed the detection of endocrine-related effects of flutamide.
...
PMID:Repeated dose (28 days) oral toxicity study of flutamide in rats, based on the draft protocol for the 'Enhanced OECD Test Guideline 407' for screening for endocrine-disrupting chemicals. 1087 97
This study was conducted to determine the low-dose effects of bisphenol A (BPA) in a rat two-generation reproduction study. Groups of 25 male and 25 female Crj: CD (SD)
IGS
rats were given BPA at 0.2, 2, 20, or 200 microg/kg/day by gastric intubation throughout the study beginning at the onset of a 10- and 2-week premating period, in F0 males and females, respectively, and continuing through the mating, gestation, and lactation periods, for two generations. There were adult (F0, F1, F2) and postnatal day (PND) 22 (F1, F2) necropsies: the oldest F2 males and females being killed at postnatal weeks 7 and 14, respectively. No compound-related clinical signs or effects on body weight or food consumption were observed in any generation. There were no compound-related changes in surface righting reflex, negative geotaxis reflex, mid-air righting reflex, pinna detachment, incisor eruption, eye opening, testes descent, preputial separation, or vaginal opening in F1 and F2 generations, or behavior in the open field or water filled multiple T-maze in the F1 generation. No test compound-related changes in estrous cyclicity, copulation index, fertility index, number of implantations, gestation length, litter size, pup weight, pup sex ratio, pup viability, or other functional reproductive measures were noted in any generation. A few significant changes in the anogenital distance (AGD) per cube root of body weight ratio were found at 0.2 and 20 microg/kg in F1 males, at 2, 20, and 200 microg/kg in F1 females, and at 20 and 200 microg/kg in F2 females. However, the changes in the AGD were consistently small (within 5% of control values), and no continuous changes in the AGD or AGD/cube root of body weight ratio were detected. There were no compound-related changes in
epididymal
sperm counts or motility in F0 and F1 males. No compound-related necropsy findings or effects on organ weight including the reproductive organs were found in any generation. Histopathologic examinations revealed no evidence of compound-related changes in any organs including the reproductive organs of both sexes. The data indicate that oral doses of BPA of between 0.2 and 200 microg/kg over 2 generations did not cause significant compound-related changes in reproductive or developmental parameters in rats.
...
PMID:Rat two-generation reproductive toxicity study of bisphenol A. 1178 Sep 58
A two-generation reproductive toxicity study with extra parameters was performed for Butyl benzyl phthalate (BBP). The compound was administered orally by gavage with the doses of 0, 100, 200, or 400 mg/kg/day to groups of 24 Crj:CD (SD)
IGS
rats of both sexes to confirm the utility of the protocol for identification of non-steroid chemicals with endocrine activity by ssessing effects on parental animals and offspring. Softening of the testes, diffuse atrophy of testicular seminiferous tubules, decreased spermatozoa and/or residual germ cells in the
epididymal
lumina were observed in the F1generation after doses more than 100 mg/kg, lowering of the F1
epididymal
weights at doses more than 200 mg/kg, along with low F0
epididymal
weights, Leydig cell hyperplasia, residual germ cells in the epidimymal lumina, and low seminal vesicle weights, small testes and epididymes, partial aplasia or aplasia of the epididymes, and Leydig cell hyperplasia in the F1 generation with 400 mg/kg. With regard to effects on the reproductive capacity, F1 parents at the dose of 400mg/kg showed a reduced fertility index and delayed preputial separation of the penis. In the offspring, lowered body weights in the F1 case, and change in anogenital distance in the F1 females and F2 males were observed at doses more than 100 mg/kg, with low splenic weights at 400 mg/kg in both generations. Thus, the utility of this protocol was confirmed. In the parental animals, the no observed effect level (NOEL) and the no observed adverse effect level (NOAEL) were less than 100 mg/kg/day, and no serious effects on the reproductive capacity were induced at doses less than 200 mg/kg/day. The NOEL and NOAEL for the growth and development of offspring were concluded to be less than 100 mg/kg/day.
...
PMID:A two-generation reproductive toxicity study of butyl benzyl phthalate in rats. 1664 42